183 related articles for article (PubMed ID: 21419438)
41. Active surveillance for prostate cancer in a veteran population.
Lee EK; Baack J; Penn H; Bromfield CT; Duchene DA; Thrasher JB; Holzbeierlein JM
Can J Urol; 2010 Dec; 17(6):5429-35. PubMed ID: 21172105
[TBL] [Abstract][Full Text] [Related]
42. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
Loblaw A; Zhang L; Lam A; Nam R; Mamedov A; Vesprini D; Klotz L
J Urol; 2010 Nov; 184(5):1942-6. PubMed ID: 20846681
[TBL] [Abstract][Full Text] [Related]
43. [Clinical problems of systematic prostate needle biopsy in the detection of prostate cancer].
Suzuki H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):16-20. PubMed ID: 12557699
[TBL] [Abstract][Full Text] [Related]
44. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
45. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
46. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen.
Cheng CW; Chan LW; Ng CF; Chan CK; Tse MK; Lai MM
Int J Urol; 2006 Apr; 13(4):463-5. PubMed ID: 16734876
[TBL] [Abstract][Full Text] [Related]
47. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
48. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
Rhoden EL; Riedner CE; Morgentaler A
J Urol; 2008 May; 179(5):1741-4. PubMed ID: 18343420
[TBL] [Abstract][Full Text] [Related]
49. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
50. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
51. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
Atmaca AF; Balbay MD
J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
[No Abstract] [Full Text] [Related]
52. [Active surveillance for screen-detected prostate cancer - a strategy for the future?].
Weissbach L; Schaefer C
Aktuelle Urol; 2010 Jul; 41(4):239-44. PubMed ID: 20661840
[TBL] [Abstract][Full Text] [Related]
53. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy.
Fujita K; Hosomi M; Tanigawa G; Okumi M; Fushimi H; Yamaguchi S
J Urol; 2011 May; 185(5):1722-7. PubMed ID: 21420119
[TBL] [Abstract][Full Text] [Related]
54. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
Tosoian JJ; Trock BJ; Landis P; Feng Z; Epstein JI; Partin AW; Walsh PC; Carter HB
J Clin Oncol; 2011 Jun; 29(16):2185-90. PubMed ID: 21464416
[TBL] [Abstract][Full Text] [Related]
55. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
Porten SP; Whitson JM; Cowan JE; Cooperberg MR; Shinohara K; Perez N; Greene KL; Meng MV; Carroll PR
J Clin Oncol; 2011 Jul; 29(20):2795-800. PubMed ID: 21632511
[TBL] [Abstract][Full Text] [Related]
56. New tests for prostate cancer.
O'Hanlon LH
J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330
[No Abstract] [Full Text] [Related]
57. Active surveillance: pitfalls to consider.
Ercole B; Parekh DJ
Arch Esp Urol; 2011 Oct; 64(8):695-702. PubMed ID: 22052752
[TBL] [Abstract][Full Text] [Related]
58. Prediction models: revolutionary in principle, but do they do more good than harm?
Vickers AJ
J Clin Oncol; 2011 Aug; 29(22):2951-2. PubMed ID: 21690474
[No Abstract] [Full Text] [Related]
59. Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
Iremashvili V; Barney SL; Manoharan M; Kava BR; Parekh DJ; Punnen S
Int J Urol; 2016 Apr; 23(4):313-7. PubMed ID: 26763088
[TBL] [Abstract][Full Text] [Related]
60. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
Connolly D; Hutton R; Keane PF
Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
